Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats
- 354 Downloads
D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a novel immunotoxin that reacts with wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFRvIII proteins overexpressed in glioblastomas. This study assessed the toxicity of intracerebral administration of D2C7-IT to support an initial Food and Drug Administration Investigational New Drug application. After the optimization of the formulation and administration, two cohorts (an acute and chronic cohort necropsied on study days 5 and 34) of Sprague–Dawley (SD) rats (four groups of 5 males and 5 females) were infused with the D2C7-IT formulation at total doses of 0, 0.05, 0.1, 0.4 μg (the acute cohort) and 0, 0.05, 0.1, 0.35 μg (the chronic cohort) for approximately 72 h by intracerebral convection-enhanced delivery using osmotic pumps. Mortality was observed in the 0.40 μg (5/10 rats) and 0.35 μg (4/10 rats) high-dose groups of each cohort. Body weight loss and abnormal behavior were only revealed in the rats treated with high doses of D2C7-IT. No dose-related effects were observed in clinical laboratory tests in either cohort. A gross pathologic examination of systemic tissues from the high-dose and control groups in both cohorts exhibited no dose-related or drug-related pathologic findings. Brain histopathology revealed the frequent occurrence of dose-related encephalomalacia, edema, and demyelination in the high-dose groups of both cohorts. In this study, the maximum tolerated dose of D2C7-IT was determined to be between 0.10 and 0.35 μg, and the no-observed-adverse-effect-level was 0.05 μg in SD rats. Both parameters were utilized to design the Phase I/II D2C7-IT clinical trial.
KeywordsD2C7-(scdsFv)-PE38KDEL Immunotoxin Convection-enhanced delivery Toxicity Rat
We thank Terri Lucas and Lena Perdue for coordinating the study, Charles Pegram, David Soule, and Xiao-Guang Zhao for the formulation preparation, and Colleen Herbst, Meredith Weksler, and Fernando Orozco for their surgical assistance. We wish to thank Christopher Means and Theo Rhodes for their detailed assessment of the animals for the Functional Observation Battery (FOB) and assistance in preparing and analyzing the FOB data. We also thank Jenna Lewis for her editorial assistance. The study was funded by the following grant from the National Institutes of Health (NIH) of the United States: P01-CA154291-03 (to D.D. Bigner). This research was also supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
Compliance with ethical standards
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 1.Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1–iv63. doi: 10.1093/neuonc/nou223 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD (2013) Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 19(17):4717–4727. doi: 10.1158/1078-0432.CCR-12-3891 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Bao X, Chandramohan V, Keir ST, Pegram CN, McLendon RE, Kuan C-T, Pastan IH, Bigner DD (2013) Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models. J Immunother Cancer 1(Suppl 1):P126. doi: 10.1186/2051-1426-1-s1-p126 CrossRefPubMedCentralGoogle Scholar
- 14.Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, Petry NA, Barboriak DP, Wong TZ, Zalutsky MR, Lally-Goss D, Bigner DD (2011) Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery 69(3):668–676. doi: 10.1227/NEU.0b013e3182181ba8 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10(3):320–329. doi: 10.1215/15228517-2008-012 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Noker PE, Fulton R, Pickett AC, Mann JF (2007) Multiple dose toxicity study of MR1-1-(MR1-1dsFvPE38KDEL, NSC-718877) in Sprague Dawley rats. Conducted at Southern Research Institute, Birmingham, Alabama and sponsored by National Cancer Institute, Bethesda, MarylandGoogle Scholar
- 24.Palestro G, Mazzucco G, Navone R, Canese MG, Coda R, Novero D, Micca FB, Leonardo E (1980) Role of the T-cell system in glomerulonephritis induced in rats by human serum albumin (HSA). An immunological and morphological study. Virchows Arch B Cell Pathol Incl Mol Pathol 35(1):19–32CrossRefPubMedGoogle Scholar